10 Best Innovative Healthcare Stocks to Buy Now
The article says U.S. healthcare lagged the market for three years, citing returns of 0.3% (2023), 0.9% (2024) and 12.5% (2025), while the S&P 500 rose 10.35% in 2026 and the sector fell 1.62%. It lists “innovative” healthcare stocks and highlights Genmab (GMAB) trial/EC approvals and Crinetics (CRNX) with UBS $55 PT and Vertex’s planned $85/share acquisition.
How this was made
The 30-second read
Why it matters
The tradable edge here is issuer-specific: GMAB’s EC marketing authorization de-risks commercialization for TEPKINLY, while CRNX’s definitive acquisition shifts valuation to deal terms and closing probability.
Market read
This is a promotional “best stocks” list, but it contains two concrete, time-relevant corporate catalysts for GMAB and CRNX.
What to watch
For GMAB, commercial uptake and payer dynamics can lag regulatory headlines; for CRNX, closing risk (regulatory/conditions) can dominate price action before Q3 2026.
Background
The article frames healthcare underperformance versus the S&P 500 as a potential “catch-up trade,” then highlights specific catalysts within its stock list.
Ticker impact
Genmab said the European Commission approved TEPKINLY plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.
Likely positive near-term bias as approval de-risks commercialization; magnitude depends on expectations already priced in.
The article cites a specific EC marketing authorization and ties it to Phase 3 EPCORE FL-1 results, which typically improves sales visibility and reduces regulatory uncertainty.
Vertex agreed to acquire Crinetics for $85.00 per share in cash, valuing the deal at about $10B and targeting a Q3 2026 close.
Supportive for CRNX as deal spread/closing odds become the key driver; volatility around regulatory/closing milestones is likely.
The text provides the definitive agreement, cash price, equity value, board approvals, and expected closing quarter—core inputs for trading the acquisition spread.
Market effects
Biotech sentiment may improve at the margin as approvals and M&A reinforce de-risking and liquidity in oncology/endocrine franchises.
European regulatory action (EC approval) can lift sentiment for EU-linked oncology developers and their US-listed peers.
Cross-border commercialization and US/Japan partnership structures highlight ongoing global demand for oncology therapies.
Counterpoint
Even with approval and a takeout, near-term upside can be capped by already-high expectations and deal-spread mean reversion.
Key entities
- public_companyGenmab A/S
Received European Commission marketing authorization for TEPKINLY in combination regimens for relapsed/refractory follicular lymphoma.
- public_companyCrinetics Pharmaceuticals
Entered a definitive agreement to be acquired by Vertex for $85.00 per share in cash.
- public_companyVertex Pharmaceuticals
Agreed to acquire Crinetics; deal terms and expected closing timing are central to CRNX trading.
